-- Mary Elizabeth Dallas
WEDNESDAY, Oct. 23 (HealthDay News) -- Five years ago,
researchers performed the first successful transplant of a
tissue-engineered airway on a 30-year-old Colombian woman. Today,
she's still doing well, according to a new follow-up report on the
The woman who received the engineered section of windpipe has
not experienced a rejection of the implanted airway, the
The mother of two received the transplant after part of her own
windpipe had collapsed due to complications from tuberculosis. An
international team of researchers led by Dr. Paolo Macchiarini
implanted a tissue-engineered trachea.
Along with his team, Macchiarini, who was at the Hospital Clinic
of Barcelona, in Spain, at the time, created the airway using cells
from a human donor trachea combined with the products of the
patient's own stem cells, as well as epithelial cells taken from a
healthy part of the woman's windpipe.
After receiving the transplant, the woman had no complications
and was discharged from the hospital 10 days after surgery. Four
months later, she still had no antidonor antibodies and did not
need to take drugs to suppress her immune system to prevent her
from rejecting the new airway. At that time, researchers cautioned
that a longer follow-up would be needed to measure the success of
Six months after surgery, the patient began to experience
persistent coughing, according to the report. Scarring in the area
of the transplant had caused a narrowing of her airway. A stent
placed to hold her airway open was effective and she no longer
experiences any symptoms, the researchers reported, although the
stent requires regular monitoring.
Now, five years later, the woman who underwent the pioneering
procedure is enjoying a normal social and working life. The
follow-up findings, published Oct. 23 in the journal
The Lancet, noted that regular tests of her lung function
and other key indicators show that she has good lung function and
has not had any complications involving her immune system.
"These results confirm what we and many patients hoped at the time of the original operation: that tissue-engineered transplants are safe and effective in the long term," Macchiarini said in a journal news release. "However, the scarring that occurred in this patient shows that long-term biomechanical stability can be improved -- something which is currently under active preclinical investigation."
"The results of a first-in-man active clinical trial will soon provide the definitive evidence that is needed before this stem-cell-based tissue-engineering technology can be translated into routine clinical practice," said Macchiarini, who currently is with the Karolinska Institute in Stockholm, Sweden.
Alan Russell, of the Disruptive Health Technology Institute at
Carnegie Mellon University and the Allegheny Health Network, in
Pittsburgh, wrote in an accompanying journal editorial that this is
"the end of the beginning for tissue engineering; the groundwork
has been laid for clinical implementation in other
Visit the U.S. National Science Foundation to learn more about
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.